Key result
Carvedilol prevents LV enlargement and systolic dysfunction in rat myocarditis, linked to decreased MMP-2 activity.
Why the study?
Does carvedilol improve cardiac function and reduce MMP-2 activity in rats with experimental autoimmune myocarditis?
Does carvedilol improve cardiac function and reduce MMP-2 activity in rats with experimental autoimmune myocarditis?
Carvedilol exerts cardioprotective effects in experimental autoimmune myocarditis by decreasing MMP-2 activity and preventing myofilament degradation, independent of inflammation suppression.
Does not support carvedilol for acute myocarditis in practice; leaves open MMP-2 inhibition as a hypothesis-generating target.
AIMS: Acute myocarditis is a potentially lethal inflammatory heart disease that frequently precedes the development of dilated cardiomyopathy and subsequent heart failure. At present, there is no effective standardized therapy for acute myocarditis, besides the optimal care of heart failure and arrhythmias in accordance with evidence-based guidelines and specific etiology-driven therapy for infectious myocarditis. Carvedilol has been shown to be cardioprotective by reducing cardiac pro-inflammatory cytokines present in oxidative stress in certain heart diseases. However, effects of carvedilol administration in acute myocarditis with its impact on matrix metalloproteinases' (MMPs) activation have not been elucidated. METHODS AND RESULTS: Carvedilol in 3 doses (2, 10, and 30 mg/kg) was given daily to 3 study groups of rats (n = 8) with experimental autoimmune myocarditis by gastric gavage for 3 weeks. In comparison to untreated rats (n = 8) with induced myocarditis, carvedilol significantly prevented the left ventricle enlargement and/or systolic dysfunction depending on the dose in study groups. Performed zymography showed enhanced MMP-2 activity in untreated rats, while carvedilol administration reduced alterations. This was accompanied by prevention of troponin I release and myofilaments degradation in cardiac muscle tissue. Additionally, severe inflammatory cell infiltration was detected in the nontreated group. Carvedilol in all doses tested, had no impact on severity of inflammation. The severity of inflammation did not differ between study groups and in relation to the untreated group. CONCLUSIONS: The protective effects of carvedilol on heart function observed in the acute phase of experimental autoimmune myocarditis seem to be associated with its ability to decrease MMP-2 activity and subsequently prevent degradation of myofilaments and release of troponin I while not related to suppression of inflammation.
No takes yet. Share an insight, caveat, or question.
Skrzypiec‐Spring et al. (2017) studied Experimental autoimmune myocarditis (n=32). Carvedilol vs. Untreated rats with induced myocarditis was evaluated on Left ventricle enlargement and/or systolic dysfunction. Carvedilol significantly prevented left ventricle enlargement and systolic dysfunction in rats with experimental autoimmune myocarditis, associated with decreased MMP-2 activity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: